Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.63 |
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.63 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.63 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.63 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393549 | 0.90 | SIRT5 (0.62) | SIRT5SIRT2SIRT1SIRT3CTSL | |
| SCHEMBL27429289 | 0.90 | SIRT2 (0.69) | SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL13449697 | 0.86 | CTSL (0.69) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL14642693 | 0.85 | CPB1 (0.58) | SIRT5SIRT2SIRT1SIRT3CTSL | |
| SCHEMBL9504309 | 0.85 | MAPT (0.65) | SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL7322113 | 0.85 | SIRT2 (0.62) | SIRT5SIRT2SIRT1SIRT3CTSL | |
| SCHEMBL7322118 | 0.85 | SIRT2 (0.62) | SIRT5SIRT2SIRT1SIRT3CTSL | |
| Hydrochloric Acid SCHEMBL7982992 | 0.84 | SIRT2 (0.61) | SIRT5SIRT2SIRT1SIRT3CTSL | |
| SCHEMBL16250362 | 0.83 | FOLH1 (0.65) | SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL16782306 | 0.83 | SIRT2 (0.66) | SIRT5SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-20 | — | — | US | disclosed |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | SIRT5 1627/4885SIRT2 3004/4885SIRT1 1885/4885 |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | SIRT5 1627/4885SIRT2 3004/4885SIRT1 1885/4885 |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | SIRT5 1627/4885SIRT2 3004/4885SIRT1 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.